ASX-listed ophthalmic technology company Nova Eye Medical expects more cataract surgeons and comprehensive ophthalmologists to uptake its glaucoma canaloplasty procedure,...
Read moreGlaukos has commenced a Phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus. The ophthalmic medical...
Read moreMyopia’s prevalence has spawned all-new innovation and unexpected collaborations. One of those is a three-way company alliance promising Australian optometrists...
Read moreLuxturna has become the first gene therapy to receive government funding in Australia, in a landmark decision that will see...
Read moreAustralian ophthalmology network PersonalEYES has become the nation’s first to offer a breakthrough method of measuring and combining data to...
Read moreThe first SightGlass Vision myopia spectacles are starting to reach the market as EssilorLuxottica and CooperCompanies announce their joint venture...
Read moreThe Therapeutic Goods Administration (TGA) has approved EIKANCE 0.01%, Australia’s first low-dose atropine eye drop for myopia progression in children...
Read moreAustralian ophthalmologists have published the first independent head-to-head comparison of two leading minimally invasive glaucoma surgery (MIGS) devices, finding no...
Read moreData from a six-year multicentre clinical trial confirms that CooperVision MiSight 1 day contact lenses provide myopia control for nearly...
Read moreGlaucoma affects an estimated 300,000 Australians but half of them don't know it. Early detection is considered vital to prevent...
Read moreInsight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.
© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited
© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited